Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock

Table 1

Included literature information form.

Include literature	Published time	Average age		Gender		Number of cases		Intervention measure
		E	C	Male	Female	E	C	E	C
Levy et al. [13]	2011	66 ± 12	64 ± 10	21	9	15	15	0.1 μg/(kg·min)^e	0.1 μg/(kg·min)^f
Pan et al. [14]	2017	64.9 ± 12.6	64.1 ± 10.8	35	13	25	23	0.005 mg/(kg·min)^a	3–12 mg/(kg·min)^c
Bruno et al. [15]	2018	68 (55–79)	66 (55–77)	38	19	27	30	0.02 μg/(kg·min)^e	0.02 μg/(kg·min)^f
Zhou et al. [16]	2012	62.3 ± 1.8	60.2 ± 2.4	21	19	20	20	60 μg/kg^g	b
Pang and Zhao [17]	2011	60.2 ± 9.8	60.2 ± 9.8	28	22	25	25	75 μg/kg^g	NA^d
Li [18]	2016	68.4 ± 11.3	70.8 ± 10.7	23	17	20	20	12 μg/kg^h	b
Chen [19]	2018	58.22 ± 5.03	60.05 ± 4.85	43	19	30	32	^f 0.05–0.19 μg/(kg·min)	5–20 μg/(kg·min)^c
Xiong et al. [20]	2016	78.76 ± 7.17	76.77 ± 6.41	40	20	30	30	^f 0.05–2.0 μg/(kg·min)	5–20 μg/(kg·min)^c
Tsagalou et al. [21]	2009	70 ± 9	69 ± 11	22	3	12	13	6 μg/(kg·min)^h	10 μg/(kg·min)^d
Yang [22]	2015	66.7 ± 6.5	65.3 ± 6.2	31	15	23	23	6 μg/kg^h	2.5 μg/(kg·min)^d
Zhang and Xiao [23]	2010	65.9 ± 0.2	65.9 ± 0.2	48	40	44	44	2–10 μg/(kg·min)^c	b
Lewis et al. [24]	2019	72.5 (59–81)	75 (67–83)	51	49	50	50	0.25 μg/(kg·min)^g	2.5 μg/(kg·min)^d
Pan et al. [25]	2018	68.36 ± 10.78	68.78 ± 10.72	46	34	40	40	12 μg/kg^h	b
Shen [26]	2017	46.0 ± 6.1	46.6 ± 6.3	26	22	24	24	12 μg/kg^h	^f 0.01–0.1 μg/(kg·min)
Tan [27]	2016	56.75 ± 12.17	58.37 ± 13.24	45	35	30	50	^f 0.05–0.19 μg/(kg·min)	10–20 μg/(kg·min)^c
Wang et al. [28]	2011	57 ± 13	57 ± 13	31	20	25	26	0.19 μg/(kg·min)^f	20 μg/(kg·min)^c
He et al. [29]	2014	63.52 ± 1.12	63.52 ± 1.12	26	21	25	22	^f 0.05–0.19 μg/(kg·min)	10–20 μg/(kg·min)^c
Li et al. [30]	2015	58.6 ± 10.1	58.6 ± 10.1	33	27	30	30	^f 0.05–0.5 μg/(kg·min)	1–20 μg/(kg·min)^c
Zhou and Zhou [31]	2019	67.96 + 5.92	68.13 + 5.38	93	29	64	58	^f 0.05–2.00 μg/(kg·min)	10–20 μg/(kg·min)^c
Li [32]	2019	69.4 ± 8.7	68.1 ± 8.2	55	31	43	43	1.5 μg/kg^a	b
Lewis et al. [33]	2015	73	73	50	50	50	50	NA^g	NA^d
Su [34]	2019	58.5 ± 3.3	59.5 ± 3.5	38	30	34	34	^f 0.1–0.5 μg/(kg·min)	^d 4.0–5.5 μg/(kg·min)
Guo et al. [35]	2017	62.75 ± 2.52	62.75 ± 2.52	37	23	30	30	12 μg/(kg·min)^h	2 μg/(kg·min)^d
Peng et al. [36]	2015	59.7 ± 1.4	58.6 ± 1.2	55	53	54	54	12 μg/kg^h	2.5 μg/(kg·min)^d
Huang et al. [37]	2018	67.2 ± 3.8	68.3 ± 4.2	37	29	33	33	12 μg/kg^h	2.5 μg/(kg·min)^d
Huang et al. [38]	2018	67.65 ± 4.69	67.59 + 4.75	55	39	47	47	12 μg/(kg·min)^h	2 μg/(kg·min)^d
Chen et al. [39]	2019	68. 05 ± 6. 73	68. 46 ± 6. 47	25	15	20	20	6 μg/kg^h	25 μg/kg^g
Yang and Sun [40]	2018	61.21 ± 2.14	61.25 ± 2.44	26	24	25	25	12 μg/(kg·min)^h	2 μg/(kg·min)^d

Note. E is the treatment group; C is the control group. ^aRecombinant human brain natriuretic peptide; ^bconventional treatment. ^cdopamine; ^ddobutamine; ^eepinephrine; ^fnorepinephrine; ^gmilrinone; ^hlevosimendan;